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macaques alters the anti-HIV-1 antibody
repertoire in the absence of viremia
Barbara C Bachler1,2, Michael Humbert1,3, Samir K Lakhashe1,3, Robert A Rasmussen1,3 and Ruth M Ruprecht1,3*Abstract
Background: We addressed the question whether live-virus challenges could alter vaccine-induced antibody
(Ab) responses in vaccinated rhesus macaques (RMs) that completely resisted repeated exposures to R5-tropic
simian-human immunodeficiency viruses encoding heterologous HIV clade C envelopes (SHIV-Cs).
Results: We examined the Ab responses in aviremic RMs that had been immunized with a multi-component
protein vaccine (multimeric HIV-1 gp160, HIV-1 Tat and SIV Gag-Pol particles) and compared anti-Env plasma Ab
titers before and after repeated live-virus exposures. Although no viremia was ever detected in these animals, they
showed significant increases in anti-gp140 Ab titers after they had encountered live SHIVs. When we investigated
the dynamics of anti-Env Ab titers during the immunization and challenge phases further, we detected the
expected, vaccine-induced increases of Ab responses about two weeks after the last protein immunization.
Remarkably, these titers kept rising during the repeated virus challenges, although no viremia resulted. In contrast,
in vaccinated RMs that were not exposed to virus, anti-gp140 Ab titers declined after the peak seen two weeks
after the last immunization. These data suggest boosting of pre-existing, vaccine-induced Ab responses as a
consequence of repeated live-virus exposures. Next, we screened polyclonal plasma samples from two of the
completely protected vaccinees by peptide phage display and designed a strategy that selects for recombinant
phages recognized only by Abs present after – but not before – any SHIV challenge. With this “subtractive
biopanning” approach, we isolated V3 mimotopes that were only recognized after the animals had been exposed
to live virus. By detailed epitope mapping of such anti-V3 Ab responses, we showed that the challenges not only
boosted pre-existing binding and neutralizing Ab titers, but also induced Abs targeting neo-antigens presented by
the heterologous challenge virus.
Conclusions: Anti-Env Ab responses induced by recombinant protein vaccination were altered by the multiple, live
SHIV challenges in vaccinees that had no detectable viral loads. These data may have implications for the
interpretation of “vaccine only” responses in clinical vaccine trials.
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According to UNAIDS/WHO, more than 2 million
people are newly infected with HIV-1 each year [1]. The
design of an effective vaccine is important to control the
global expansion of the AIDS pandemic [2]. In the con-
text of vaccine efficacy in humans, only the RV144 trial
showed promising results so far [3] and recent follow-up
studies identified vaccine-induced correlates of protec-
tion [4,5]. Additionally, biologically relevant non-human
primate (NHP) models are used in HIV-1/AIDS research
to gain information about vaccine-induced immunity
[6,7]. In contrast to clinical studies in humans, NHPs
can be deliberately challenged with well characterized
virus inocula. This allows a subsequent detailed analysis
of virus-specific consequences on pre-existing (vaccine-
induced) immune responses.
Previously, we described different immunization/chal-
lenge studies in rhesus macaques (RMs) that were
vaccinated with recombinant protein immunogens (multi-
meric HIV-1 clade C (HIV-C) gp160, HIV-1 Tat and SIV
Gag-Pol particles). Upon repeated challenge with the
heterologous R5-tropic simian-human immunodeficiency
viruses encoding HIV-1 clade C envelopes (SHIV-Cs), all
controls became infected and developed high peak
viremia, whereas some vaccinees remained aviremic
throughout ([8-12] and unpublished). Here, we focused on
the antibody (Ab) responses in vaccinees that had resisted
all mucosal challenges completely and asked two ques-
tions: i) is there a quantitative difference in the anti-Env
Ab titers after versus before live-virus exposures in ani-
mals without detectable viremia? And ii) is there a quali-
tative difference in the Ab responses after versus before
live-virus exposures in the same animals due to newly
induced Abs targeting neo-antigens that were presented
by the heterologous challenge virus? To address these
issues, we decided to dissect the Ab responses in com-
pletely protected RMs further and to take an imprint of
the Ab paratopes after virus challenges using recombinant
phage libraries encoding random peptides.
Results
Dynamics of anti-Env Ab responses in vaccinated RMs
To test whether live-virus exposures could induce quan-
titative changes in the vaccine-induced Ab responses in
RMs where the virus failed to cause any detectable
viremia, we first investigated Env-specific plasma Ab ti-
ters at time points before and after virus challenge. We
examined plasma samples of two vaccine-protected
RMs, RRi-11 and RTr-11, that had been enrolled in the
same vaccine/challenge study [12] and challenged mul-
tiple times with the R5 clade C SHIV-1157ipEL-p [13]
(Group 1 in Figure 1A, B and Table 1). Monkey RRi-11
fulfilled all criteria for sterilizing immunity, whereas
RTr-11 showed anamnestic cellular immune responsescompatible with cryptic infection ([12] and Table 1). As
a control, we also investigated anti-Env binding Ab titers
in eight animals that had been part of an unpublished
immunogenicity study (Group 2, Figure 1C, D). Import-
antly, these animals were immunized similarly as the
monkeys from Group 1, including the same adjuvant
(incomplete Freund’s adjuvant, IFA). To allow a direct
comparison of both groups, we adjusted the time points
for Group 2 and designated the time of last protein
immunization as week −2. For both groups, we tested
plasma collected at weeks −1 and 0 and up to 8 weeks
post last protein immunization (weeks 1, 2 and 6). Most
animals showed an increase of anti-gp140 Ab titers
between week −1 (light red) and week 0 (dark red)
(Figure 1B, D), which reflects the expected boosting of
Ab responses during the two weeks after the last protein
immunization (week −2). Yet, when we examined the
anti-gp140 binding Ab responses at later time points,
only the two vaccinees exposed to live virus showed a
continuing increase of anti-gp140 Ab titers (Group 1,
blue bars, Figure 1B). In contrast, the Ab levels in Group
2 controls peaked at the two weeks post last immuni-
zation and declined during the time window that corre-
sponds to the virus challenge in Group 1 (green bars,
Figure 1D). Taken together, we conclude that the third
protein immunization led to a boosting of anti-gp140
Ab responses, which reached a peak within two weeks
(week 0). Importantly, these Env-specific Ab titers con-
tinued to increase only in the RMs exposed repeatedly
to live virus, although no viremia was ever detected.
These data suggest a boosting of anti-Env Abs by virus
challenges that did not result in systemic infection.
Next, we extended our analysis and examined the anti-
Env Ab binding titers in three additional vaccinees that
were also completely protected but had been enrolled in
different vaccine/challenge studies ([8-11] and unpub-
lished). The immunogens and challenge viruses used are
listed in Table 1. Although the multigenic immunogen
composition had varied among the studies, all of the
vaccinees had received the same multimeric HIV-C
gp160. When we compared the vaccine-induced anti-
gp140 Ab titers (Methods) with the Ab responses against
the same protein but measured after virus exposures, we
observed a statistically significant increase of anti-Env
specific Abs not only for the two RMs mentioned, RRi-
11 and RTr-11 (P < 0.0001 and P = 0.002, respectively),
but also for RM RAt-9 (P = 0.03), which had been chal-
lenged with a different virus (Figure 1E). Also, the
protected RM ROb-12, which had resisted five low-dose
challenges with the tier 2 SHIV-2873Nip (unpublished
data), showed a trend towards higher Env-specific
plasma Ab titers after the live-virus encounters
(P = 0.08). In the fifth aviremic vaccinee, RQe-10, the
anti-Env binding Ab titers did not change.
Figure 1 Anti-Env Ab responses in vaccinated RMs before and after virus challenge. A. Time line of vaccine/challenge study [12]. In red,
immunization phase; in blue, challenge phase. Plasma samples were collected at weeks −1, 0, 1, 2 and 6. B. Quantitative ELISA to determine Env-
specific Ab titers in two vaccine-protected RMs. In red, time points post 3rd immunization and pre-challenge; in blue, time points post challenge.
C. Time line of immunogenicity study (unpublished). The last protein immunization was designated as week −2, so that the subsequent weeks
would correspond to the study in (A). D. Quantitative ELISA to determine Env-specific Ab titers in eight vaccinated, but not challenged RMs. In
red, 1 or 2 weeks post 3rd immunization; in green, subsequent time points. E. The gp140CN54-specific Ab titers were compared before and after
live-virus challenges in five completely protected vaccinees. The challenge viruses used are indicated. Height of each bar, average titer from three
independent assays; error bars, standard error of the mean (SEM). P values are shown (P < 0.05 was considered significant). F. Subtractive
biopanning. Three rounds of selection were performed to identify Ab epitopes linked to live-virus exposure. Each round of selection consists of
(1) positive selection, (2) negative selection and (3) amplification of the selected phages. Light gray, the Fc portion of all Abs. Dark gray, Fab
portion of anti-RM IgG immobilized onto paramagnetic beads via the Fc. Positive selection used week 7 plasma from a protected animal. In dark
blue, Fab portions of the live-virus induced Abs and the corresponding phages. Positively selected recombinant phages were counter-selected
with plasma from the same vaccinee but collected at week 0 (containing vaccine-induced Abs only). In red, Fab portions of negative selector Abs
and the corresponding bound phages. Purple or yellow phages, unspecific phages bound to anti-RM Ab or beads, respectively.
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Table 1 Immune status of vaccinees after all live-virus challenges
Level of
protection
Animal
name
Virological
outcome
Interpretation Immunogens Challenge viruses
(challenge route)
Enrolled in
study
Complete ROb-12 Aviremic Cryptic infection HIV-C gp160 and gp145
+ SIV Gag overlapping
synthetic peptides (OSP)
+ HIV Tat OSP
+ SIV Nef OSP
Multiple low-doses with
SHIV-2873Nip (intrarectal) [14]
unpublished
RAt-9 Aviremic Cryptic infection HIV-C gp160
+ SIV Gag-Pol particles
+ HIV Tat
Single low-dose with SHIV-1157ip
(oral) and single high-dose with
SHIV-1157ipd3N4 (intrarectal) [15]
[8-10]
RQe-10 Aviremic Sterilizing
immunity
Listeria monocytogenes
expressing SIV gag
+ Ad5hr encoding SIV gag
+ HIV-C gp160
+ HIV Tat
Multiple low-doses with
SHIV-1157ipEL-p (intrarectal) [13]
[11]
RRi-11 Aviremic Sterilizing
immunity
HIV-C gp160
+ SIV Gag-Pol particles
+ HIV Tat
Multiple low-doses and one high-dose
with SHIV-1157ipEL-p (intrarectal) [13]
[12]
RTr-11 Aviremic Cryptic infection
Partial RBr-11 Lower peak
viremia
Chronic systemic
infection
RGe-11 Aviremic during
low-dose
challenges
2 low-level blips
(<104 copies/ml)
None RDo-11 No protection Chronic systemic
infection
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Ab responses for animals RAt-9, RQe-10, RRi-11
and RTr-11 before and after live-virus exposures
[16]. We observed a similar boosting of Ab levels
in the same animals (again no changes for RQe-10).
Combined, these data show measurable boosting of
at least two different HIV-1 targets, Env and Tat,
after live SHIV-C exposures – although no viral
loads were ever detected in these animals through-
out the time course of observation that ranged from
one to six years.
Probing the virus-specific Abs: Subtractive biopanning
Based on these quantitative changes, we addressed
the question whether the virus challenge had also
induced a qualitative change in the Abs responses.
In other words, we sought to examine whether
there were Abs with new specificities present only
after – but not before – any exposure to live virus.
To probe the paratopes of these new Abs, we fur-
ther dissected the Ab repertoire in the two aviremic
animals mentioned above (RRi-11 and RTr-11),
using recombinant phage libraries encoding random
peptides. To identify Ab responses only present
after exposure to the challenge virus (in this case
SHIV-1157ipEL-p [12]), we devised a novel selection
strategy based upon random peptide phage displayand termed “subtractive biopanning”: Positive selec-
tion used plasma from a completely protected RM
after all low-dose exposures (week 7). This was
followed by negative counter-selection with plasma
from the same animal collected two weeks after the
last protein boost, corresponding to just before the
first virus challenge (week 0) (Figure 1F). We hy-
pothesized that removing phages recognized by
vaccine-induced Abs would enrich for phages bind-
ing to Abs generated during the repeated mucosal
virus challenges. Three rounds of alternating posi-
tive/negative selection were performed. Peptide in-
serts of selected recombinant phages (phagotopes)
were sequenced and aligned with the Env sequence
of the immunogen (HIV1084i gp160) or the chal-
lenge strain (SHIV-1157ipEL-p) to search for mim-
icry (mimotopes).
Depending on the positive selector used, different
motifs were identified (data not shown). However,
one recurring motif shared by RRi-11 and RTr-11
could be assigned to the V3 crown (linear align-
ment, Figure 2A), and the corresponding mimotopes
were termed wk7-V3 mimotopes. To verify that the
latter represented epitopes of Abs induced by the
virus challenges rather than Abs induced by the
gp160 1084i immunogen, we cross-tested 14 differ-
ent plasma samples from each aviremic animal for
Figure 2 Mapping of anti-V3 binding Abs. A. Sequences of recombinant phages were assigned to V3 crown of HIV1084i or SHIV-1157ipEL-p.
Gray shading, linear homologies; blue shading/white letters, amino acid difference between the two HIV-C envelopes (M307I). V3 mimotopes
isolated using week 7 plasma (wk7-V3 mimotopes) were tested for plasma Ab binding using 14 time points of RRi-11 and RTr-11. Negative
control, pre-immune plasma; weeks −1 and 0, vaccine-induced Ab responses; weeks 1–7, also include Ab responses induced during low-dose
virus challenges; weeks 8–30, Ab responses after all challenges. Data illustrate results from two independent assays. Binding patterns are shown in
form of a heat-map. OD signals 3x higher than signals detected with the wildtype phage control were considered positive. B. V3 amino-acid
sequences of HIV1084i, SHIV-1157ipEL-p and SHIVSF162P4. The two HIV clade C envelopes of SHIV-1157ipEL-p and HIV1084i differ in only one
residue in the V3 crown (M307I; HXB2 numbering scheme [17]; highlighted in blue). SHIVSF162P4 shares the same gp120-sequence as HIVSF162 [18]
and has three mutations compared with the 1084i immunogen (M307I (blue), and R308P and Q315K (gray)). C. Sequences of synthetic peptide
sets used for plasma Ab titration and peptide absorption analysis. Peptides corresponding to consensus clade C sequence differed in two amino-
acid residues compared with immunogen-related peptides (HIV1084i): M307I (blue) and A316T (gray). D. Plasma samples of five vaccinees [12]
were assessed for binding Ab specificities at weeks 0 and 7 using two different V3 peptide sets (red bars, 1084i; blue bars, consensus clade C).
Height of each bar, average titer calculated from three independent assays; error bars, standard error of the mean (SEM). Statistically significant
differences between weeks 0 and 7 are indicated (if P < 0.05).
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presented in the form of a heat-map (Figure 2A).
None of the wk7-V3 mimotopes were recognized by
plasma Abs present before live-virus encounters
(naïve, week −1 or week 0 samples). However, once
the vaccinees were exposed to SHIV-1157ipEL-p forthe first time (week 1), 8 out of 14 wk7-V3
mimotopes were specifically recognized by plasma
Abs, with increasing binding reactivities at week 2.
Interestingly, these responses were strongly boosted
by the single high-dose rechallenge with the same
SHIV-C (Figure 2A). Overall, these data confirmed
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enriched for mimotopes only recognized by Abs
present after live SHIV-C exposures.
Mapping of vaccine- versus virus-specific V3 Ab epitopes
The vaccinees had encountered two different HIV-C Env
sequences, HIV1084i as an immunogen and SHIV-
1157ipEL-p as challenge virus. HIV1084i and SHIV-
1157ipEL-p Envs are distinct and only share 78% amino
acid (AA) homology [12]. Importantly, they differ in the
V3 crown at position 307 (methionine to isoleucine
switch; M307I) (Figure 2B), which affects one of three
V3 core residues recently described as essential for the
recognition of broadly neutralizing antibodies (bnAbs)
[19]. For epitope mapping, we used two different peptide
sets corresponding to the V3 crown (Figure 2C): one
was identical to the HIV1084i immunogen sequence,
while the other set represented a consensus clade C se-
quence and contained M307I as in the heterologous
challenge virus, SHIV-1157ipEL-p. Of note, the consen-
sus C V3 peptide set shows another AA switch (A316T)
in the V3 circlet. However, this area is more variable and
therefore less likely targeted by bnAbs [19].
Using the linear V3 peptides (Figure 2C), we perfor-
med binding ELISAs to confirm that the low-dose
SHIV-1157ipEL-p exposures had altered Ab titers. To-
wards this end, we analyzed plasma samples collected at
weeks 0 and 7 in the two vaccine-protected RMs, RRi-11
and RTr-11 (Figure 2D). As a comparison, we also ex-
amined three vaccinees that had been part of the same
study ([12], Table 1 and time line in Figure 1A) but had
detectable viral RNA: RGe-11 exhibited two transient,
low-level blips (<104 viral RNA copies/ml) but lymph
node biopsies were virus negative. RBr-11 developed
chronic systemic infection but had lower peak viremia
compared with the controls and RDo-11 was chronically
infected without any signs of protection (Table 1).
Remarkably, the aviremic animals RRi-11 and RTr-11
showed significantly higher immunogen-related V3-
specific ELISA titers after the fifth virus challenge com-
pared with the titers before the first live-virus encounter
(Figure 2D, red bars; P = 0.035 and P = 0.005, respect-
ively). As expected, the three other vaccinees that had
detectable viral loads (RGe-11, RBr-11 and RDo-11)
also showed a statistically significant boosting using
the immunogen-related 1084i V3 peptides (red bars,
P = 0.04, P = 0.008 and P = 0.012, respectively). Thus, the
5x low-dose challenges with SHIV-1157ipEL-p boosted
the vaccine-induced anti-V3 binding Ab titers in all five
animals tested.
When we used the consensus C V3 peptides (blue
bars), which contain the critical mutation (M307I) that
is present in the challenge virus but not in the immuno-
gen, we detected an increase of anti-V3 binding Abs inthe two aviremic vaccinees, RRi-11 (P = 0.046) and RTr-
11 (P = 0.008), as well as in RBr-11 (P = 0.012) and RDo-
11 (P = 0.046). The anti-consensus C V3 Ab titers did
not change for RM RGe-11 when samples from weeks 7
and 0 were compared (Figure 2D). Taken together, our
data indicate that the five SHIV-1157ipEL-p challenges
significantly boosted the pre-existing anti-V3 binding
Ab responses. Importantly, this was also observed in
two protected RMs, although no viremia was detected
throughout.
Boosting of vaccine-induced anti-V3 nAbs in the absence
of viremia
To test whether the multiple SHIV-1157ipEL-p chal-
lenges had not only altered Ab binding activity but also
the vaccine-induced nAb activity, we examined plasma
samples of weeks 0 and 7 for nAb titers. Although no
viremia was ever detected in animals RRi-11 and RTr-
11, their 50% inhibitory concentration (IC50) against the
challenge virus increased after the 5× virus encounters
(Figure 3A; white bars, IC50 of weeks 0 vs. 7). For RRi-
11, the IC50 was insignificantly 1.5-fold higher. For RTr-
11, we detected a statistically significant 3.3-fold increase
(P = 0.01) at week 7. Clearly, live-virus exposures boosted
pre-existing nAb responses in this aviremic vaccinee.
Next, we examined whether the increased neutraliza-
tion titer noticed after live SHIV-C exposures could be
linked to anti-V3 nAb responses. Thus, we absorbed the
neutralizing activity by incubating plasma in the pres-
ence/absence of the different V3 peptide sets shown in
Figure 2C. Absorption with the immunogen-related
1084i V3 peptides reduced the neutralizing activity of
the week 7 plasma by 79% in RRi-11 (P = 0.009) but not
at all in RTr-11 (Figure 3A; red bars). Importantly, ab-
sorption with the consensus C V3 peptides significantly
lowered the neutralizing activity after but not before
live-virus exposure in both aviremic animals (blue bars;
P = 0.004 and 0.02, respectively). Neither the partially
protected nor the non-protected monkeys showed
changes in nAb titers or V3 reactivity (RGe-11, RBr-11,
and RDo11, data not shown). Taken together, the pep-
tide absorption data imply that nAbs with new target
specificity had developed between weeks 0 and 7, espe-
cially in animal RTr-11 (neo-antigen reactivity; gray box
and asterisk in Figure 3A).
Induction of new cross-neutralizing anti-V3 antibodies in
the absence of viremia
We reasoned that 5× live-virus exposures might have in-
duced anti-V3 nAbs that cross-neutralize a heterologous,
non-clade C virus and tested plasma samples of weeks
0 and 7 for neutralizing activity against the clade B
SHIVSF162P4 [21]. We used the peptide absorption de-
scribed above to link neutralization to anti-V3 Abs and
Figure 3 Induction and boosting of cross-neutralizing anti-V3 Abs in the absence of viremia. Plasma samples (weeks 0 and 7) were tested
for neutralizing activity against the challenge virus, SHIV-1157ipEL-p (A) and the heterologous clade B SHIVSF162P4 (B) by TZM-bl assay [20].
Neutralization titers are expressed as the reciprocal plasma dilution inhibiting 50% of virus infection (IC50). Each bar represents the average titer of
at least two independent assays using triplicates of each sample and error bars show the SEM. Plasma nAb titers were compared between weeks
0 (before live-virus challenges) and 7 (after 5x multiple low-dose challenges). Plasma samples were incubated with either medium (plasma only,
white bars) or one of the two peptide sets (red bars, 1084i V3; blue bars, consensus clade C V3) and IC50 values were calculated. In case of a
decreased IC50 (depletion of neutralizing activity), percentages illustrate the degree of inhibition reached with each peptide set. P-values are
shown (significance after Bonferroni correction, P < 0.025). Gray box and asterisks indicate neoantigen reactivity.
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compared with the HIV1084i immunogen (M307I,
R308T and Q315R; see Figure 2B). Overall, the 5×
SHIV-1157ipEL-p challenges did not increase neutraliz-
ing activity against SHIVSF162P4 in the two aviremic RMs
(Figure 3B; white bars, IC50 of weeks 0 vs. 7). We also
saw no statistically significant differences in IC50 levels
at week 7 when using the immunogen-related 1084i V3
peptides (red bars). In contrast, peptide absorption
showed highly significant drops in IC50 values after incu-
bation with the consensus C V3 peptides (blue bars,
P = 0.02 for RRi-11 and P = 0.006 for RTr-11). These
data are consistent with an expansion of target specifi-
city in both protected animals (neo-antigen reactivity for
RTr-11; gray box and asterisk in Figure 3B) at week 7.No significant changes were seen for the partially
protected animal RGe-11 (data not shown).
Overall, we conclude that the 5× live-virus exposures: i)
boosted vaccine-induced anti-1084i V3 binding Ab titers,
ii) induced anti-V3 nAb responses against the challenge
virus SHIV-1157ipEL-p, and iii) changed the V3 loop spe-
cificity of nAbs against heterologous SHIVSF162P4 in two
animals without any signs of viremia.
Discussion
Here we describe: i) a quantitative change in the Env-
specific plasma Ab titers in four out of five persistently
aviremic vaccinees, ii) subtractive biopanning with re-
combinant phages encoding random peptides as a new
tool to dissect qualitative (virus-induced) changes in the
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mals, iii) an increase of vaccine-induced anti-V3 binding
Abs and induction of novel, cross-neutralizing anti-V3
Abs due to live SHIV-C encounters in animals that had
remained virus-free.
Different immunization studies performed by our
group yielded a cohort of five vaccinees that resisted
multiple live SHIV-C exposures completely. Here, we
dissected the Env-specific Ab responses in these mon-
keys. More specifically, we investigated the consequences
of live-virus challenges on the strength and specificity of
vaccine-induced Ab responses in the absence of any de-
tectable viral load. Unexpectedly, we detected higher
Env-specific binding Ab titers in four out of five
aviremic RMs after they had been exposed to live SHIV-
C. The boosting of Ab responses was independent of the
challenge route. Similar effects were observed after oral
(for animal RAt-9 [8-10]) and intrarectal challenges
(for all the other monkeys tested).
To verify that the increased anti-Env Ab titers were a
direct consequence of the virus challenges, we compared
the dynamics of anti-gp140 Ab responses in vaccinated
RMs with or without subsequent exposures to live virus.
As expected, we detected a vaccine-induced boost of Ab
responses about two weeks after the last protein
immunization in both groups of animals. Remarkably,
these titers kept increasing during the repeated virus
challenges although no viremia ensued. In contrast,
immunization without subsequent virus challenges
resulted in the expected increase in anti-gp140 Ab levels
that peaked at week 2 post-immunization and continu-
ously declined thereafter. These data confirmed a live-
virus induced increase of pre-existing, vaccine-induced
Ab responses.
We sought to examine the Ab repertoire in two of
the protected animals further and determined whether
the live-virus challenges only boosted the pre-existing,
vaccine-induced responses or also induced new Abs
against neo-antigens represented by the Env proteins on
the challenge virus particles. Phage display [22] has been
used to analyze humoral immune responses in the
context of chronic infections with immunodeficiency
viruses [23-27]. Here, we designed a novel subtractive
biopanning strategy to probe the paratopes of virus-
induced Abs in vaccine-protected animals. We hypothe-
sized that depleting phages recognized by Abs present
after immunization but before any virus exposures
would select for phages recognized by live virus-induced
Abs only. We performed subtractive biopannings using
polyclonal plasma samples from completely protected
vaccinees and analyzed the selected phagotopes for simi-
larities to Env sequences. This approach allowed us to
identify the V3 crown as an epitope specifically recog-
nized by week 7 but not week 0 Abs and shared by thetwo aviremic vaccinees, although subtractive biopanning
revealed other Env regions for these vaccinees individu-
ally (data not shown).
Recently, the V3 crown and its conserved structural ele-
ments that are involved in co-receptor binding were
shown to be important targets for bnAbs, including
mAbs 447/52-D, 2219, 3074, 33B2, 33C6 [19,28-30] and
HGN194 [31]; the latter also provided complete cross-
clade protection against SHIV-C acquisition in vivo [32].
Together with the novel bnAbs, PG9 and PG16, targeting
quaternary epitopes formed by the V2 and V3 loops in tri-
meric Env [33], the V3 loop is now considered again as
target for vaccine development (reviewed in [28]).
By phage ELISA, we confirmed that the V3 mimotopes
isolated by subtractive biopanning were only recognized
after but not before the first virus challenge. Import-
antly, these responses were also boosted by the re-
challenge with a high-dose of the same challenge virus.
These data indicate that both low- and high-dose chal-
lenges can induce a similar boosting effect.
Our detailed analysis of anti-V3 responses using the
actual V3 peptides revealed a significant boosting of
immunogen-induced anti-HIV 1084i V3 binding Abs
after the multiple low-dose challenges in five out of five
vaccinees tested. Importantly, the same boosting was
noticed in the two completely protected animals. This
is remarkable considering that no viremia was ever
detected for >3 years. In addition to these altered bind-
ing Ab titers, we also observed an increase in neutraliz-
ing activity against the challenge virus in the same
aviremic RMs. Peptide absorption linked these increased
nAb titers to anti-V3 responses. Interestingly, most of
the induced cross-neutralizing anti-V3 Abs targeted the
antigenically different version of the V3 crown presented
by the challenge virus. Based on these results, we
propose that the multiple live-virus exposures boosted
anti-HIV-1 responses and altered their specificity in the
absence of any detectable viremia.
Pre-existing antiviral immunity has been considered
problematic for the recognition of antigenically diverse
strains by the “primed” immune system. This idea of a
compromised immune system was first discussed in the
context of influenza virus antigens [34] and termed
Original Antigenic Sin (OAS) [35]. Ab formation during
initial influenza infections in childhood was believed to
greatly influence future Ab formation against newer
strains encountered later [34]. More specifically, vaccin-
ation with one strain of influenza virus and subsequent
exposure to a heterologous strain would induce anam-
nestic Ab responses against the initial strain [35]. Later,
Nara and coworkers expanded the concept of OAS to
the model of deceptive imprinting and defined it as a
mechanism leading to a fixed state of immunity which
in turn fails to adapt to a changing, but similar pathogen
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ally restricted B-cell responses due to immunodominant
epitopes found on the original antigen (reviewed in
[38]). With regard to HIV-1 infections, it was postulated
that initial vaccine-induced nAb responses would target
immunodominant epitopes of variable gp120 regions
(especially the V3 loop), which mutate due to immune
selection pressure [36]. Thus, nAb responses would be
limited to the primary virus variant, which is considered
potentially problematic during chronic HIV-1 infection,
as well as for the formation of effective nAb responses
against non-homologous HIV-1 strains in vaccine recipi-
ents [36-39]. Yet, we [40] and others [41-43] gave evi-
dence that the occurrence of OAS is not absolute.
Investigating the anti-V3 binding Ab repertoire in
vaccine-protected RMs, we indeed detected a statistically
significant boosting of the initial vaccine-induced bind-
ing Abs after live-virus encounters with the heterologous
strain, supporting the concept of OAS. However, our
data do not imply a limitation in subsequent Ab re-
sponses against non-homologous virus strains as sug-
gested by the model of deceptive imprinting [36,37].
Based upon the initial selection of V3 mimotopes and
their specific recognition of plasma samples after but
not before live SHIV-C exposures, we demonstrate a
change in the Ab repertoire as a consequence of live-
virus encounters. This neo-antigen reactivity was then
confirmed indirectly by peptide absorption analysis
showing the induction of nAbs against an antigenically
different version of the same V3 epitope. Thus, despite
the pre-existing anti-V3 Abs present after immunization,
virus-challenged RMs that never developed viremia pro-
duced cross-neutralizing anti-V3 Abs targeting the epi-
tope version presented by the challenge virus.
Of note, the boosting of virus-specific Ab responses as a
consequence of live-virus exposures that failed to cause
detectable viremia was not restricted to Env only.
According to our recent work [16], multiple live-virus ex-
posures also affected anti-Tat Ab responses; we showed
that mimotopes displaying the N-terminus of HIV-1 Tat
were only recognized by Abs of protected vaccinees, RRi-
11 and RTr-11, after the live-virus exposures (week 7), but
not on the day of challenge (week 0). Subsequent quantita-
tive ELISAs using the full-length HIV-1 Tat protein and
Tat peptides confirmed an increase of anti-Tat Abs after
multiple exposures to SHIV-C in three out of four
aviremic vaccinees (RRi-11, RTr-11 and RAt-9). These
data indicate that the virus challenges altered Ab re-
sponses against at least two different HIV-1 proteins, Env
and Tat, in the absence of systemic infection.
Animals ROb-12, RAt-9, RRi-11 and RTr-11 were
never viremic. How did the multiple low-dose virus
challenges alter the vaccine-induced anti-Env and anti-
Tat Ab repertoire in these animals? Theoretically, threemechanisms could be responsible: i) cryptic infection of
target cells and their subsequent lysis. This may have
produced sufficiently high concentrations of challenge
virus proteins to induce Abs with altered specificities;
ii) formation of immune complexes of virions and/or
soluble protein with pre-existing, vaccine-induced Abs
followed by efficient binding to and presentation by
Fc-gamma receptor (FcγR)-expressing cells; iii) a com-
bination of the two mechanisms.
In order to estimate potential mechanisms that may
have been involved, we first employed an ultrasensitive
HIV-1 gp120 antigen capture ELISA and used parental
SHIV-1157ip gp120 [30] as reference protein. Total
gp120 concentration of the virus stock solubilized in dis-
ruption buffer was only 35 pg per challenge virus dose.
This total amount of gp120 is about 106-107 less than
what has been used for standard immunizations in
humans or macaques [44-48], making boosting via sol-
uble Env a highly unlikely mechanism – especially since
no adjuvant was involved in contrast to the standard
vaccination/boosting protocols [44-48]. Moreover, the
virus-induced boosting effect was not only detected in
animals from one study [12] but in four animals derived
from three different studies ([8,12] and unpublished).
Thus, we propose that this observation is not virus-
stock dependent since the challenge virus strains varied
among the different studies.
Cryptic infection is expected to boost antiviral cellular
immunity. This was observed in some of the vaccine-
protected RMs (RTr-11, RAt-9, ROb-12). In contrast,
vaccinee RRi-11 had no anamnestic cellular immune
responses and thus fulfilled the criteria for sterilizing
immunity. For this animal, we propose that vaccine-
induced nAbs not only blocked initial infection of target
cells but also led to the formation of virion-antibody
complexes (reviewed in [49]). Such opsonized virions
may then have been taken up by follicular dendritic cells
in lymph nodes, which in turn resulted in more effective
presentation of Env epitopes to B cells (reviewed in
[50,51]). Thus, we suggest that virions – although unable
to cause systemic infection – might have acted as effective
immunogens in the form of antigen-antibody complexes.
Ab-covered virions also altered the anti-Tat Ab re-
sponses. According to Monini et al. [52], HIV-1 Tat can
form a specific molecular complex with trimeric Env
and hence is found on virion Env spikes. This observa-
tion would explain the boosting of pre-existing or induc-
tion of novel anti-Tat Ab responses.
In the current study, we examined the Env-specific Ab
responses in five completely protected vaccinees and
chose two of them to investigate the virus-induced con-
sequences on pre-existing Ab responses further. At this
point, it should be emphasized that well studied individ-
ual cases, as the protected monkeys described above,
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potential solutions to the problems of prevention and/or
cure of retroviral infections. To illustrate the power of
case reports, we point to the description of a monkey
with breakthrough SIV infection [53], HIV-1 superinfec-
tion in a relatively recently infected individual [54], and
the “Berlin patient” [55].
In summary, we described a boosting of pre-existing,
vaccine-induced Ab responses in immunized macaques
that remained aviremic throughout all heterologous
SHIV-C challenges. Furthermore, detailed epitope map-
ping revealed newly induced Abs specific for epitopes
formed only in the challenge virus.
Conclusions
Exposures to live virus that fail to cause viremia can
nevertheless result in changes in the Ab repertoire ini-
tially induced by vaccination. This is an important find-
ing with implications for the analysis of immunogenicity
data for clinical vaccine trials in humans. Sub-threshold
virus exposure due to high risk behaviour may broaden
the vaccine-induced Ab repertoire in the absence of sys-
temic infection or seroconversion. Repeated live-HIV-1
exposures may complicate the interpretation of “vac-
cine-only” immune responses, which will be difficult to
investigate. Thus, further well-controlled challenge
studies in biological relevant primate models will be
necessary to elucidate the underlying mechanism(s) of
low-dose pathogen interactions with vaccinated hosts
without overt infection.
Methods
Animals
Indian-origin RMs (Macaca mulatta) were housed at
the Yerkes Regional Primate Research Center (Atlanta,
GA, USA). All procedures were approved by the Animal
Care and Use Committees of Emory University and
the Dana-Farber Cancer Institute (DFCI). To examine
Env-specific Ab responses induced by live-virus expos-
ure, plasma samples were collected from RMs that had
been either part of a vaccine/challenge study or an im-
munogenicity study. Animals of the former included
ROb-12 (unpublished), RAt-9 [8-10], RQe-10 [11], RRi-
11, RTr-11, RGe-11, RBr-11 and RDo-11 [12]. The im-
mune status of these vaccinees as well as immunogens
and challenge viruses used are summarized in Table 1.
Group 1 animals [12] described in Figure 1 had re-
ceived three protein immunizations, consisting of HIV-1
gp160, HIV-1 Tat, and SIV Gag-Pol particles (weeks−
33, -27 and −2). Starting two weeks after the third
protein immunization (week 0), all RMs were given five
weekly low-dose intrarectal (i.r.) challenges of SHIV-
1157ipEL-p (weeks 0–4, 8,000 50% tissue culture infec-
tious doses (TCID50, measured by TZM-bl assay [20]).At week 7, animals without evidence of viremia were
rechallenged i.r. with a single high dose of the same
virus (1.5 × 105 TCID50).
Group 2 animals shown in Figure 1 (RDs-12, RFg-12,
RYc-12, RGn-12, RNu-12, RMc-12, RJd-12, RGv-12; un-
published) had been treated according to a similar
immunization protocol as the vaccinated and challenged
animals (involving HIV-1 1084i gp160, SIV Gag-Pol parti-
cles, HIV-1 Tat) with the addition of SIV Nef overlapping
synthetic peptides (OSP). All recombinant protein immu-
nogens were given in incomplete Freund’s adjuvant (IFA).
Protein ELISA
Microtiter plates (Greiner-Bio-One GmbH, Frickenhausen,
Germany) were coated with CN54-gp140 (Polymun, Sci-
entific GmbH, Klosterneuburg, Austria); 1 μg/ml in 50 μl/
well carbonate-bicarbonate buffer (Sigma-Aldrich, St.
Louis, MO, USA). After blocking for 2 h at room
temperature with 3% casein (Sigma-Aldrich), plasma sam-
ples were diluted 3-fold, added to the plates (in blocking
buffer) and incubated for 3 h at room temperature. After-
wards, Ab binding was detected using a HRP-conjugated
anti-monkey IgG (1 h at room temperature, 1:2,000 in
blocking buffer; Sigma-Aldrich) and o-Phenylenediamine
dihydrochloride (OPD; Amresco Inc., Cochran, Solon,
OH, USA) +H2O2. After stopping the reaction with 1 N
H2SO4, plates were read at 490/620 nm. Binding Ab titers
were calculated by linear regression and defined as recip-
rocal plasma dilution with an absorbance 5× higher than
the background absorbance, detected with the autologous
pre-immune plasma.
Since the five completely protected RMs had been en-
rolled in four different immunization/challenge studies,
the time points of the samples collected varied slightly
in Figure 1E. For the “before any live-virus challenge”
time point we always used week 0, but in case of RAt-9,
we analyzed week −2 because week 0 was not available.
For the “after live-virus challenge” samples we analyzed
the following time points: ROb-12 plasma from week 6,
RAt-9 plasma from week 30, RQe-10, RRi-11 and RTr-
11 plasma from weeks 6 or 7, respectively.
Subtractive biopanning
Plasma samples of vaccinated, protected animals were
used to identify specific Ab epitopes by peptide phage-
display. Paramagnetic beads (Dynabeads M-280 tosylac-
tivated; Invitrogen, Carlsbad CA, USA) were coated with
rabbit anti-monkey IgG (as previously described [26])
and pre-incubated with polyclonal RM plasma (collected
at week 7, positive selection). After overnight incubation
with the original phage-display libraries (7mer, cyclic
7mer, 12mer; New England Biolabs, Ipswich MA, USA),
bound phages were eluted by pH shift with 0.2 M
glycine-HCl pH 2.2 supplemented with 1 mg/ml bovine
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HCl pH 9.1 (Sigma-Aldrich). Eluted phages were used in
a negative selection (plasma sample from week 0).
Remaining phages were amplified in Escherichia coli
(ER2738, New England Biolabs), precipitated overnight
at 4°C (20% PEG-8000/2.5 M NaCl; Fisher Scientific,
Fair Lawn NJ, USA) and subjected to two more rounds
of selection. After the third positive selection, phages
were titered, single clones were picked and then tested
by phage ELISA for specific binding. Single-stranded
DNA of positive clones was sequenced. Peptide se-
quences were grouped into motifs and assigned to the
gp160 sequence of the vaccine- (HIV1084i) or challenge
strain (SHIV-1157ipEL-p).Phage ELISA and cross-reactivity profile of mimotopes
Phage ELISAs were performed as previously published
[26]. As a negative control, M13KO7 helper phages
(New England Biolabs) without peptide insert were in-
cluded (wild type phage). Phage peptides mimicking the
V3 crown were evaluated according their binding activ-
ity to polyclonal plasma Abs of different time points
before and after virus challenges. Optical density (OD)
signals at least 3× higher than signals detected with the
negative control were considered positive and the cross-
reactivity profile of each mimotope was expressed as
color-coded heat-map.Synthetic peptides
Peptides corresponding to the V3 consensus clade C se-
quence were obtained from the NIH AIDS Reagent and
Reference Reagent Program (15 amino acids (AA) long,
overlapping by 11 AA). Peptides corresponding to
HIV1084i V3 were 15 AA long, overlapping by 10 AA
(CHI-Scientific, Maynard, MA, USA) (sequences see
Figure 2C). A pool of three overlapping peptides was
used (peptide set). As negative control, a scrambled
C-terminal gp120 peptide was included (24 AA, GVTK
YIPGSIPVEGLKSHKAGSYK, Molecular Biology Core
Facilities, DFCI, Boston, MA).Peptide ELISA
Microtiter plates were coated with a pool of three over-
lapping V3 peptides or the negative control peptide
(total concentration per peptide set, 2 μg/ml in 100 μl/
well carbonate-bicarbonate buffer). After blocking for 2
h at room temperature with 3% casein, plasma samples
were diluted 2-fold and added to the plates (in blocking
buffer). Ab detection and calculation of binding Ab titers
as described for the protein ELISA. Ab titers were com-
pared at weeks 0 and 7.Depletion of nAbs using synthetic peptides
Plasma samples were incubated in the presence/absence
of V3 peptides (based on [40]) and tested against SHIV-
1157ipEL-p and SHIVSF162P4 by TZM-bl assay [20].
Briefly, a total of 5,000 cells/well were seeded overnight.
Plasma samples were diluted 2-fold and incubated for 1
h at 37°C with a pool of three overlapping peptides (total
concentration, 50 μg/ml), the control peptide, or an
equal volume of growth medium. Virus was incubated
with the Ab/peptide mixture for 1 h at 37°C and after-
wards transferred into the 96-well flat-bottom plate
containing TZM-bl cells. After maximally 20 h, medium
was exchanged. After another 24 h, Bright-Glo luciferase
substrate (Promega, Madison, WI, USA) was used to
measure luciferase activity. Neutralization titers are cal-
culated with regard to autologous pre-immune plasma
samples and expressed as the reciprocal plasma dilution
inhibiting 50% of virus infection (IC50). The ability of
peptides to block nAbs is calculated as the percent re-
duction in neutralization titers relative to that of the cor-
responding plasma sample without peptide incubation.
Detection of Env protein in the challenge virus
preparation
100 μl/well of the original virus preparation were used in
the HIV-1 gp120 Antigen Capture Assay (Advanced Bio-
science Laboratories, Rockville, MD, USA) according to
the manufacturer’s instructions. For more accurate estima-
tion of the SHIV-1157ipEL-p gp120 content, we included
the parental 1157ip gp120 protein as reference [30].
Statistical analysis
Statistics were calculated using a paired, two-tailed
Student’s t-test comparing the significance between Ab
titers before and after five low-dose challenges. Differ-
ences with P < 0.05 were considered statistically signifi-
cant. Differences in nAb titers detected with plasma
samples in the absence/presence of certain peptides were
calculated using an unpaired, two-tailed Student’s t-test
(including Bonferroni correction: P < 0.025 were consi-
dered statistically significant). All statistical analysis
was performed using GraphPad Prism 5 for Windows,
GraphPad Software.
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